MYWOT
Child safety
Confidence
Trustworthiness
Confidence
MALICIOUS CONTENT INDICATORS
Investors.biogen.com most likely does not offer any malicious content.
Secure connection support
HTTPS
Investors.biogen.com provides SSL-encrypted connection.
ADULT CONTENT INDICATORS
Investors.biogen.com most likely does not offer any adult content.
Popular pages
-
Annual Reports | Financial Information | Investor Relations | Biogen
The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts.
-
BIOGEN TO REPORT FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS FEBRUARY 15, 2023 | Biogen
January 18, 2023 • News Release Cambridge, Mass.— Biogen Inc. (Nasdaq:BIIB) today announced it will report fourth quarter and full year 2022 financial results...
-
Biogen Reports Fourth Quarter and Full Year 2022 Results | Biogen
February 15, 2023 • News Release August 4, 2023 FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Wo...
-
News | Biogen
Rare and Genetic Diseases
-
Presentations | Investor Relations | Biogen
Interim Results From the Ongoing RESPOND Study Jun 30, 2023 Evaluating Efficacy and Safety of Tofersen in Adults with SOD1-ALS: Results from the Phase 3 VALOR Trial and Open-Label Extension at ENCALS ...
-
Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint
January 27, 2022 • News Release The companies will continue with their exclusive agreements, including for commercialization of their current portfolio CAMBRI...